BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Policy

  Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List

  Zai Lab Limited announced that the 2023 National Reimbursement Drug List released by China’s National Healthcare Security Administration has been updated to include the following medicines and indications.

  December 12, 2023

   · 

  9 min read
• Pharm Country

  HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

  HUTCHMED Limited announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration, on January 1, 2024 the updated National Reimbursement Drug List will continue to include ELUNATE® and SULANDA® at the same terms as the current two-year agreement.

  December 12, 2023

   · 

  6 min read
• BioCapital

  Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® ‘s Seventh Indication and BYVASDA®'s Eighth Indication

  Innovent Biologics, Inc. announces that, the National Reimbursement Drug List has been updated to renew and include the seventh indication of PD-1 inhibitor TYVYT® in negotiation list, and include the eighth indication of BYVASDA® in general list.

  December 12, 2023

   · 

  11 min read